ethyl (E)-3-[4-hydroxy-2,6-bis(methoxymethyl)-5-pyrimidinyl]-2-propenoate | 499775-91-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: ethyl (E)-3-[4-hydroxy-2,6-bis(methoxymethyl)-5-pyrimidinyl]-2-propenoate
• 英文别名: ethyl (E)-3-[2,4-bis(methoxymethyl)-6-oxo-1H-pyrimidin-5-yl]prop-2-enoate
• CAS: 499775-91-6
• 化学式: C₁₃H₁₈N₂O₅
• 分子量: 282.296
• InChiKey: GLCKBJGUJDMCHH-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  86.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl (E)-3-[4-hydroxy-2,6-bis(methoxymethyl)-5-pyrimidinyl]-2-propenoate 在 三乙胺 、 三氯氧磷 作用下， 以 正丁醇 、 苯 为溶剂， 反应 8.0h， 生成 8-(4-bromo-benzyl)-2,4-bis(methoxymethyl)pyrido[2,3-d]pyrimidin-7(8H)-one
  参考文献：
  名称：

  Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects

  摘要：

  Three novel metabolites of the angiotensin-II (A-II) receptor antagonist tasosartan have been identified in humans, and the syntheses and pharmacologic profiling of these metabolites are reported. Each metabolite bound the human A-II receptor with IC(50)s between 20 and 45 nM. The in vivo effects of these compounds in attenuating the pressor response to angiotensin-II challenge in anesthetized rats were also investigated. An unsaturated diol metabolite exhibited in vivo efficacy at intravenous doses of 1 and 3 mg/kg, while the other metabolites, both carboxylic acids, had no significant effect at the same doses. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00303-7
• 作为产物：
  描述：

  2,6-bis(methoxymethyl)-4-pyrimidinol 在 palladium diacetate 碘 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 6.75h， 生成 ethyl (E)-3-[4-hydroxy-2,6-bis(methoxymethyl)-5-pyrimidinyl]-2-propenoate
  参考文献：
  名称：

  Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects

  摘要：

  Three novel metabolites of the angiotensin-II (A-II) receptor antagonist tasosartan have been identified in humans, and the syntheses and pharmacologic profiling of these metabolites are reported. Each metabolite bound the human A-II receptor with IC(50)s between 20 and 45 nM. The in vivo effects of these compounds in attenuating the pressor response to angiotensin-II challenge in anesthetized rats were also investigated. An unsaturated diol metabolite exhibited in vivo efficacy at intravenous doses of 1 and 3 mg/kg, while the other metabolites, both carboxylic acids, had no significant effect at the same doses. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00303-7